PCN66 Cost-Effectiveness of Denosumab Versus Zoledronic Acid for Skeletal-Related Event (SRE) Reduction in Bone-Metastatic Prostate Cancer (mPC) in the UK

Nov 1, 2012, 00:00 AM
10.1016/j.jval.2012.08.2106
https://www.valueinhealthjournal.com/article/S1098-3015(12)03820-X/fulltext
Section Title : Cancer
Section Order : 759
First Page : A420
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)03820-X&doi=10.1016/j.jval.2012.08.2106
HEOR Topics :
Tags :
Regions :